Návratnosť kapitálu spoločnosti ProMIS Neurosciences
Aká je hodnota metriky Návratnosť kapitálu spoločnosti ProMIS Neurosciences?
Hodnota metriky Návratnosť kapitálu spoločnosti ProMIS Neurosciences, Inc. je -49.45%
Aká je definícia metriky Návratnosť kapitálu?
Return on capital employed (ROCE) je finančný ukazovateľ, ktorý meria rentabilitu spoločnosti a účinnosť spoločnosti vo využívaní vlastného kapitálu.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
Návratnosť kapitálu spoločností v sektore Health Care sektor na OTC v porovnaní so spoločnosťou ProMIS Neurosciences
Čomu sa venuje spoločnosť ProMIS Neurosciences?
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Firmy s metrikou návratnosť kapitálu podobnou spoločnosti ProMIS Neurosciences
- Hodnota metriky Návratnosť kapitálu spoločnosti Genasys Inc je -49.78%
- Hodnota metriky Návratnosť kapitálu spoločnosti Hookipa Pharma Inc je -49.72%
- Hodnota metriky Návratnosť kapitálu spoločnosti Choom je -49.69%
- Hodnota metriky Návratnosť kapitálu spoločnosti ANGLE Plc je -49.52%
- Hodnota metriky Návratnosť kapitálu spoločnosti 4SC AG je -49.47%
- Hodnota metriky Návratnosť kapitálu spoločnosti Beyond Meat Inc je -49.46%
- Hodnota metriky Návratnosť kapitálu spoločnosti ProMIS Neurosciences je -49.45%
- Hodnota metriky Návratnosť kapitálu spoločnosti Shineco Inc je -49.44%
- Hodnota metriky Návratnosť kapitálu spoločnosti Calliditas Therapeutics AB (publ) je -49.42%
- Hodnota metriky Návratnosť kapitálu spoločnosti AUX Resources je -49.38%
- Hodnota metriky Návratnosť kapitálu spoločnosti Argenica Therapeutics je -49.26%
- Hodnota metriky Návratnosť kapitálu spoločnosti Rice Acquisition je -49.24%
- Hodnota metriky Návratnosť kapitálu spoločnosti Digimarc je -49.11%